Bacteriophages, viruses that infect and replicate inside prokaryotic cells are essentially the most plentiful life kinds in the atmosphere, but the overwhelming majority of them haven’t been correctly reported and even found. Almost all reported bacteriophages infecting the Enterobacteriaceae household, with Escherichia coli being the foremost topic of research, have been remoted from wastewater, sewage, and effluent sources.
In the current examine, we targeted on the distribution and biodiversity of Shigella phages in an aquatic ecosystem. While no Shigella micro organism was recovered from the Yangtze River, three lytic phages have been remoted from this ecosystem and have been subjected to organic, morphological, and genomic traits.
Comparative genomics and phylogenetic analyses demonstrated that vB _SflM_004 isolate belongs to Myoviridae household, Felixounavirus genus of Ounavirinae subfamily, vB_SdyM_006 was labeled beneath the identical household, nevertheless, it’s advised to be in a brand new genus beneath Tevenvirinae subfamily with another associated bacteriophages. vB_SsoS_008 phage belongs to the Siphoviridae household, Tunavirus genus, Tunavirinae subfamily.
The phages didn’t harbor any genes concerned in the lysogenic cycles and confirmed a excessive temperature and pH stability. The biodiversity of the remoted phages extremely means that continued isolation on non-model members of Enterobacteriaceae household is important to completely perceive bacteriophage range in aquatic environments.
An Engineered Reporter Phage for the Fluorometric Detection of Escherichia coli in Ground Beef
Despite enhanced sanitation implementations, foodborne bacterial pathogens nonetheless stay a significant risk to public well being and generate excessive prices for the meals trade. Reporter bacteriophage (phage) programs have been considered a robust expertise for diagnostic assays for his or her extraordinary specificity to focus on cells and cost-effectiveness.
Our examine launched an enzyme-based fluorescent assay for detecting the presence of E. coli utilizing the T7 phage engineered with the lacZ operon which encodes beta-galactosidase (β-gal). Both endogenous and overexpressed β-gal expression was monitored utilizing a fluorescent-based methodology with 4-methylumbelliferyl β-d-galactopyranoside (MUG) because the substrate.
The an infection of E. coli with engineered phages resulted in a detection restrict of 10 CFU/mL in floor beef juice after 7 h of incubation. In this examine, we demonstrated that the overexpression of β-gal coupled with a fluorogenic substrate can present a simple and delicate strategy to detect the potential organic contamination in meals samples. The outcomes additionally advised that this method will be utilized to detect E. coli strains remoted from environmental samples, indicating a broader vary of bacterial detection.
Analysis of a Novel Bacteriophage vB_AchrS_AchV4 Highlights the Diversity of Achromobacter Viruses
Achromobacter spp. are ubiquitous in nature and are more and more being acknowledged as rising nosocomial pathogens. Nevertheless, so far, solely 30 full genome sequences of Achromobacter phages can be found in GenBank, and practically all of these phages have been remoted on Achromobacter xylosoxidans. Here, we report the isolation and characterization of bacteriophage vB_AchrS_AchV4. To the most effective of our information, vB_AchrS_AchV4 is the primary virus remoted from Achromobacter spanius. Both vB_AchrS_AchV4 and its host, Achromobacter spanius RL_4, have been remoted in Lithuania.
VB_AchrS_AchV4 is a siphovirus, because it has an isometric head (64 ± 3.2 nm in diameter) and a non-contractile versatile tail (232 ± 5.4). The genome of vB_AchrS_AchV4 is a linear dsDNA molecule of 59,489 bp with a G+C content material of 62.8%. It accommodates no tRNA genes, but it consists of 82 protein-coding genes, of which 27 don’t have any homologues in phages. Using bioinformatics approaches, 36 vB_AchrS_AchV4 genes got a putative perform. An extra 4 have been annotated primarily based on the outcomes of LC-MS/MS.
Comparative analyses revealed that vB_AchrS_AchV4 is a singleton siphovirus with no shut relations amongst identified tailed phages. In abstract, this work not solely describes a novel and distinctive phage, but in addition advances our information of genetic range and evolution of Achromobacter bacteriophages.
Genetic and Chemical Engineering of Phages for Controlling Multidrug-Resistant Bacteria
Along with the extreme use of antibiotics, the emergence and unfold of multidrug-resistant micro organism has develop into a public well being drawback and a terrific problem vis-à-vis the management and therapy of bacterial infections. As the pure predators of micro organism, phages have reattracted researchers’ attentions. Phage remedy is considered one of essentially the most promising various methods to struggle pathogens in the post-antibiotic period. Recently, genetic and chemical engineering strategies have been utilized in phage modification.
Among them, genetic engineering consists of the expression of toxin proteins, modification of host recognition receptors, and interference of bacterial phage-resistant pathways. Chemical engineering, in the meantime, includes crosslinking phage coats with antibiotics, antimicrobial peptides, heavy steel ions, and photothermic issues. Those advances tremendously broaden the host vary of phages and improve their bactericidal effectivity, which sheds gentle on the appliance of phage remedy in the management of multidrug-resistant pathogens. This evaluate reviews on engineered phages by way of genetic and chemical approaches. Further, we current the obstacles that this novel antimicrobial has incurred.
Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer
Evolution of nanomedicine is the re-design of artificial and organic carriers to implement novel theranostic platforms. In latest years, bacteriophage analysis favors this course of, which has opened up new roads in drug and gene supply research. By displaying antibodies, peptides, or proteins on the floor of completely different bacteriophages by way of the phage show method, it’s now attainable to unravel particular molecular determinants of each most cancers cells and tumor-associated microenvironmental molecules. Downstream functions are manifold, with peptides being employed most of the occasions to functionalize drug carriers and enhance their therapeutic index.
Bacteriophages themselves have been confirmed, in this situation, to be good carriers for imaging molecules and therapeutics as nicely. Moreover, manipulation of their genetic materials to stably vehiculate suicide genes inside most cancers cells considerably modified views in gene remedy. In this evaluate, we offer examples of how amenable phages can be utilized as anticancer brokers, particularly as a result of their systemic administration is feasible. We additionally present some insights into how their immunogenic profile will be modulated and exploited in immuno-oncology for vaccine manufacturing.
Extraordinary Multi-Organismal Interactions Involving Bacteriophages, Bacteria, Fungi, and Rotifers: Quadruple Microbial Trophic Network in Water Droplets
Our observations of predatory fungi trapping rotifers in activated sludge and laboratory tradition allowed us to find a sophisticated trophic community that features predatory fungi armed with micro organism and bacteriophages and the rotifers they prey on. Such a community appears to be widespread in numerous habitats, though it stays largely unknown because of its microscopic measurement. In this examine, we remoted and recognized fungi and micro organism from activated sludge.
We additionally observed plentiful, virus-like particles in the atmosphere. The fungus developed absorptive hyphae inside the prey. The micro organism confirmed the power to enter and exit from the hyphae (e.g., from the traps into the caught prey). Our observations point out that the micro organism and the fungus share vitamins obtained from the rotifer. To slender the vary of bacterial strains remoted from the mycelium, the consequences of micro organism supernatants and lysed micro organism have been studied. Bacteria remoted from the fungus have been succesful of immobilizing the rotifer.
 Antibody) CDw17(HuLy-m13) Antibody |
|
BNC811088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF680R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC811088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF680R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCAP1088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCAP1088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCB1088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), Biotin conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCB1088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), Biotin conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC471088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF647 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC471088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF647 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC551088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF555 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC551088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF555 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC431088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF543 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC431088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF543 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC881088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF488A conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC881088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF488A conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC941088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF594 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC941088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF594 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCH1088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCH1088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCP1088-250 |
Biotium |
250uL |
EUR 383 |
|
Description: Primary antibody against CDw17(HuLy-m13), PerCP conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC041088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF405S conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC041088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF405S conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNCR1088-250 |
Biotium |
250uL |
EUR 383 |
|
Description: Primary antibody against CDw17(HuLy-m13), RPE conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNUB1088-100 |
Biotium |
100uL |
EUR 209 |
|
Description: Primary antibody against CDw17(HuLy-m13), Concentration: 0.2mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNUB1088-500 |
Biotium |
500uL |
EUR 458 |
|
Description: Primary antibody against CDw17(HuLy-m13), Concentration: 0.2mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC681088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF568 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC681088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF568 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC701088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF770 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC701088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF770 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC051088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF405M conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC051088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF405M conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC611088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF660R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC611088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF660R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC401088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF640R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC401088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF640R conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC801088-100 |
Biotium |
100uL |
EUR 199 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF680 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNC801088-500 |
Biotium |
500uL |
EUR 544 |
|
Description: Primary antibody against CDw17(HuLy-m13), CF680 conjugate, Concentration: 0.1mg/mL |
CDw17(HuLy-m13) Antibody |
|
BNUM1088-50 |
Biotium |
50uL |
EUR 395 |
|
Description: Primary antibody against CDw17(HuLy-m13), 1mg/mL |
) Anti-Complement Factor B Monoclonal Antibody (M13/12) |
|
CTA-128-100ug |
Creative Biolabs |
100ug |
Ask for price |
|
Description: Mouse anti-complement Factor B monoclonal antibody (M13/12) for WB, IA, IP. |
Anti-Complement Factor B Monoclonal Antibody (M13/12) |
|
CTA-128-1mg |
Creative Biolabs |
1mg |
Ask for price |
|
Description: Mouse anti-complement Factor B monoclonal antibody (M13/12) for WB, IA, IP. |
 Polyclonal Goat anti-GST α-form |
|
GST-ANTI-1 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST μ-form |
|
GST-ANTI-2 |
Detroit R&D |
50 uL |
EUR 280 |
 Polyclonal Goat anti-GST p-form |
|
GST-ANTI-3 |
Detroit R&D |
50 uL |
EUR 280 |
) Filamentous Phages M13 Antibody (Biotin) |
|
abx022499-025ml |
Abbexa |
0.25 ml |
EUR 1017 |
|
|
 M13 Phage Titration ELISA Kit |
|
55R-PRPHAGE |
Fitzgerald |
96 tests |
EUR 693 |
|
Description: Enzyme Immunoassay for the Quantitative Determination of purified M13 Bacteriophage Particles |
 M13/fd/F1 Filamentous Phages antibody |
|
10R-2437 |
Fitzgerald |
5 mL |
EUR 286 |
|
Description: Mouse monoclonal M13/fd/F1 antibody |
 M13 + fd + F1 Filamentous Phages antibody |
|
10R-M101a |
Fitzgerald |
500 ug |
EUR 943 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody |
M13 + fd + F1 Filamentous Phages antibody |
|
10R-M101ax |
Fitzgerald |
100 ug |
EUR 392 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody |
 (M13), Clone: 1E12) Monoclonal FOXO3A Antibody (monoclonal) (M13), Clone: 1E12 |
|
AMM03559G |
Leading Biology |
0.05mg |
EUR 484 |
|
Description: A Monoclonal antibody against Human FOXO3A (monoclonal) (M13). The antibodies are raised in mouse and are from clone 1E12. This antibody is applicable in IHC, IF, E |
 (M13), Clone: 3A4) Monoclonal TCL1A Antibody (monoclonal) (M13), Clone: 3A4 |
|
AMM04180G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A Monoclonal antibody against Human TCL1A (monoclonal) (M13). The antibodies are raised in mouse and are from clone 3A4. This antibody is applicable in E |
 (M13), Clone: 2A6) Monoclonal KCNE1 Antibody (monoclonal) (M13), Clone: 2A6 |
|
AMM06087G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A Monoclonal antibody against Human KCNE1 (monoclonal) (M13). The antibodies are raised in mouse and are from clone 2A6. This antibody is applicable in IP, E |
) Enterobacteria phage M13 Attachment protein G3P (III) |
|
1-CSB-YP303116ECY |
Cusabio |
-
EUR 679.00
-
EUR 335.00
-
EUR 2172.00
-
EUR 1051.00
-
EUR 1442.00
-
EUR 435.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Enterobacteria phage M13 Attachment protein G3P(III) expressed in Yeast |
) M13/fd/F1 Filamentous Phages antibody (Biotin) |
|
10R-2378 |
Fitzgerald |
50 ug |
EUR 194 |
|
Description: Mouse monoclonal M13/fd/F1 antibody |
) M13 + fd + F1 Filamentous Phages antibody (biotin) |
|
61R-M101aBT |
Fitzgerald |
250 uL |
EUR 531 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody (biotin) |
) M13 + fd + F1 Filamentous Phages antibody (FITC) |
|
61R-M101aFT |
Fitzgerald |
250 uL |
EUR 721 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody (FITC) |
) M13 + fd + F1 Filamentous Phages antibody (HRP) |
|
61R-M101aHRP |
Fitzgerald |
750 uL |
EUR 525 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody (HRP) |
M13 + fd + F1 Filamentous Phages antibody (HRP) |
|
61R-M101aHRPS |
Fitzgerald |
1 ml |
EUR 701 |
|
Description: Mouse monoclonal M13 + fd + F1 Filamentous Phages antibody (HRP) |
) Enterobacteria phage M13 Tail virion protein G9P (IX) |
|
1-CSB-EP301675ECY |
Cusabio |
-
EUR 611.00
-
EUR 309.00
-
EUR 1827.00
-
EUR 939.00
-
EUR 1218.00
-
EUR 397.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Enterobacteria phage M13 Tail virion protein G9P(IX) expressed in E.coli |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-100ug |
|
QP7036-100ug |
EnQuireBio |
100ug |
EUR 771 |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-10ug |
|
QP7036-10ug |
EnQuireBio |
10ug |
EUR 355 |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-1mg |
|
QP7036-1mg |
EnQuireBio |
1mg |
EUR 2531 |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-200ug |
|
QP7036-200ug |
EnQuireBio |
200ug |
EUR 1224 |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-500ug |
|
QP7036-500ug |
EnQuireBio |
500ug |
EUR 1614 |
 Recombinant Bacteriophage Fibritin Protein, His-SUMO, E.coli-50ug |
|
QP7036-50ug |
EnQuireBio |
50ug |
EUR 473 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-100ug |
|
QP7339-ec-100ug |
EnQuireBio |
100ug |
EUR 707 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-10ug |
|
QP7339-ec-10ug |
EnQuireBio |
10ug |
EUR 326 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-1mg |
|
QP7339-ec-1mg |
EnQuireBio |
1mg |
EUR 2303 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-200ug |
|
QP7339-ec-200ug |
EnQuireBio |
200ug |
EUR 1115 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-500ug |
|
QP7339-ec-500ug |
EnQuireBio |
500ug |
EUR 1514 |
 Recombinant Bacteriophage Endolysin Protein, His-SUMO, E.coli-50ug |
|
QP7339-ec-50ug |
EnQuireBio |
50ug |
EUR 435 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-100ug |
|
QP9483-ye-100ug |
EnQuireBio |
100ug |
EUR 788 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-10ug |
|
QP9483-ye-10ug |
EnQuireBio |
10ug |
EUR 362 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-1mg |
|
QP9483-ye-1mg |
EnQuireBio |
1mg |
EUR 2747 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-200ug |
|
QP9483-ye-200ug |
EnQuireBio |
200ug |
EUR 1260 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-500ug |
|
QP9483-ye-500ug |
EnQuireBio |
500ug |
EUR 1804 |
 Recombinant Bacteriophage Attachment protein G3P Protein, His, Yeast-50ug |
|
QP9483-ye-50ug |
EnQuireBio |
50ug |
EUR 480 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-100ug |
|
QP7414-ec-100ug |
EnQuireBio |
100ug |
EUR 707 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-10ug |
|
QP7414-ec-10ug |
EnQuireBio |
10ug |
EUR 326 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-1mg |
|
QP7414-ec-1mg |
EnQuireBio |
1mg |
EUR 2303 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-200ug |
|
QP7414-ec-200ug |
EnQuireBio |
200ug |
EUR 1115 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-500ug |
|
QP7414-ec-500ug |
EnQuireBio |
500ug |
EUR 1514 |
 Recombinant Bacteriophage Helix-destabilizing protein Protein, His-SUMO, E.coli-50ug |
|
QP7414-ec-50ug |
EnQuireBio |
50ug |
EUR 435 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-100ug |
|
QP7417-ec-100ug |
EnQuireBio |
100ug |
EUR 707 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-10ug |
|
QP7417-ec-10ug |
EnQuireBio |
10ug |
EUR 326 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-1mg |
|
QP7417-ec-1mg |
EnQuireBio |
1mg |
EUR 2303 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-200ug |
|
QP7417-ec-200ug |
EnQuireBio |
200ug |
EUR 1115 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-500ug |
|
QP7417-ec-500ug |
EnQuireBio |
500ug |
EUR 1514 |
 Recombinant Bacteriophage Recombination protein uvsY Protein, His-SUMO, E.coli-50ug |
|
QP7417-ec-50ug |
EnQuireBio |
50ug |
EUR 435 |
 Recombinant Bacteriophage Tail virion protein G9P Protein, His-SUMO, E.coli-100ug |
|
QP6944-100ug |
EnQuireBio |
100ug |
EUR 771 |
 Recombinant Bacteriophage Tail virion protein G9P Protein, His-SUMO, E.coli-10ug |
|
QP6944-10ug |
EnQuireBio |
10ug |
EUR 355 |
 Recombinant Bacteriophage Tail virion protein G9P Protein, His-SUMO, E.coli-1mg |
|
QP6944-1mg |
EnQuireBio |
1mg |
EUR 2531 |
 Recombinant Bacteriophage Tail virion protein G9P Protein, His-SUMO, E.coli-200ug |
|
QP6944-200ug |
EnQuireBio |
200ug |
EUR 1224 |
 Recombinant Bacteriophage Tail virion protein G9P Protein, His-SUMO, E.coli-500ug |
|
QP6944-500ug |
EnQuireBio |
500ug |
EUR 1614 |
The strongest unfavorable impact on rotifer mobility was proven by a combination of Bacillus sp. and Stenotrophomonas maltophilia. The involvement of bacteriophages in rotifer searching was demonstrated primarily based on molecular analyses and was mentioned. The described case appears to be a unprecedented quadruple microbiological puzzle that has not been described and remains to be removed from being understood.
